The Hindu Business Line : Strides-Aspen in supply pact with GlaxoSmithKline

Bangalore, July 23 Strides Arcolab Ltd’s joint venture with South Africa’s Aspen Pharmacare has struck a global licensing and supply agreement with GlaxoSmithKline.

The deal will take 1,200 branded products of Strides, Aspen and their 50:50 venture, Onco Therapeutics Ltd, to 95 emerging markets; GSK gets access to new, low-cost products and a push into these markets, according to releases from Strides and GSK.

The pact was inked through the eight-month-old OTL, the Strides’ Vice-Chairman and CEO, Mr Arun Kumar, said. The first set of products would be launched in 2010.

OTL will license intellectual property and supply finished dosage forms. It will receive intellectual property-development costs and share profits from sales.

GSK would source, register and distribute and market them. Strides keeps the Indian market, and Aspen the sub-Saharan regions.

GSK termed it a ‘transformational agreement’ that enlarges and drives its portfolio in these markets.

Mr Arun Kumar said it was early to gauge the revenue impact; “The deal reflects the value created out of the joint venture (with Aspen). OTL’s robust pipeline augurs well for future growth.”

Related Stories:
Strides Arcolab, Aspen seal Latam deal

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Weekend rains likely over peninsula

Rupee surges by 65 paise

Near-term trend positive in rupee

Insurance players now see scope for more FDI

Strides-Aspen in supply pact with GlaxoSmithKline

Steel Authority of India (Rs 146): Buy

Day Trading Guide

Cotton export contracts need to be registered

Cashew apple seen a viable source to produce ethanol

‘Short-term profitability of general insurance firms could be hit’

Disinvestment process may gain speed

Markets on a song

Market experts doubt sustainability of current rally

Tariff hikes: TRAI mulls raising ‘minimum protection period’

Slowdown in Indian aviation may end in a year: Boeing